Living With Mesothelioma: Coping Strategies to Find Hope

Living With Mesothelioma: Coping Strategies to Find Hope

Mesothelioma is a cancer caused by exposure to asbestos. One key question remains unanswered. How do diagnosed patients experience living with mesothelioma? A new study in Health Psychology aimed to explore the mesothelioma patient experience. Data from 22 different research studies were analyzed. The coping strategies highlighted here provide hope for mesothelioma patients and caregivers. The results bring awareness of the patient experience, coping processes, and support pathways. Two Coping Strategies to Support a Mesothelioma Patient The best coping strategies help patients reclaim a sense of mental calm, individual autonomy, and meaning. These strategies can also reduce the trauma of living with mesothelioma. Patients who accepted the diagnosis fully were more optimistic than those in denial. Patients who accepted the … Continue reading Living With Mesothelioma: Coping Strategies to Find Hope »

Predicting How a Patient Will Respond to Mesothelioma Treatment

Predicting How a Patient Will Respond to Mesothelioma Treatment

Malignant pleural mesothelioma is a rare cancer. Early diagnosis is challenging. Treatments are the first clinical option in the advanced disease stage. A doctor’s initial clinical response says a lot about the patient’s prognosis. It may even represent a useful way to identify patients with a better long-term outcome. A new Italian study from the Journal of Clinical Medicine looks at this possibility. First Mesothelioma Treatment Response Options Scientists looked at the initial treatment response in 46 mesothelioma patients who had pleural mesothelioma. None of these patients had surgery as an option because their tumors were considered inoperable. The doctor’s initial treatment response included a CT scan and clinical examination. This examination was usually after 2–3 cycles of drug therapy. … Continue reading Predicting How a Patient Will Respond to Mesothelioma Treatment »

Comparing 3 Standard Treatments for Mesothelioma

Comparing Three Frontline Treatments for Mesothelioma

There are three standard treatments for malignant pleural mesothelioma. Patients and doctors want to know which is more effective. A new study from the Davidoff Cancer Center in Israel sought to do just that. This study compared three clinical trials of the standard treatments recommended for malignant mesothelioma. All three treatments involved different chemotherapy drugs. Treatment A was cisplatin plus pemetrexed vs cisplatin. Treatment B was cisplatin plus pemetrexed plus bevacizumab vs cisplatin plus pemetrexed. And Treatment C was nivolumab plus ipilimumab vs cisplatin plus pemetrexed. Urgent Need to Identify Effective Treatment Strategies Malignant pleural mesothelioma is the primary cancer of the pleural lining. It is caused by exposure to asbestos. It affected more than 30,000 patients globally in 2020. … Continue reading Comparing 3 Standard Treatments for Mesothelioma »

Lower Platelet Count Linked to Longer Mesothelioma Survival

Lower Platelet Count Linked to Higher Survival Rates

A high platelet count may not bode well for people battling malignant pleural mesothelioma. New evidence suggests that survival rates may be higher for mesothelioma patients with a lower platelet count. This news comes from the Kocaeli University which analyzed malignant mesothelioma patients between 2008 and 2014. They wanted to know if certain clinical characteristics could predict longer patient survival. Platelets and Health Mesothelioma is a rare form of cancer. It develops from cells of the mesothelium, the lining that covers many of the internal organs of the body. While it is uncommon, it has a high mortality rate. Smaller than either red or white blood cells, platelets are the components in blood that facilitate clotting. The normal range for platelet … Continue reading Lower Platelet Count Linked to Longer Mesothelioma Survival »

The First FDA-Approved Mesothelioma Drug in 15 Years

The First FDA-Approved Mesothelioma Drug in 15 Years

On October 2, 2020, the first FDA-approved mesothelioma drug in 15 years hit the market. They approved a new combination of drugs for mesothelioma. The combination of nivolumab with ipilimumab is now considered the first-line treatment. It is the go-to for adult patients with unresectable malignant pleural mesothelioma. The FDA based approval on results from an open-label clinical trial. The results of a new study show outcomes of Mesothelioma patients over the last 2 years. This often was often six cycles of chemotherapy. Patient survival using this new combination of drugs was an average of 18.1 months. This was an increase from 14.1 months for patients who only received chemotherapy. More clinical pharmacology data also supported an alternative dosing regimen. … Continue reading The First FDA-Approved Mesothelioma Drug in 15 Years »

Maximizes Your Immune Cell Response with High-Intensity Exercise

High-Intensity Exercise Maximizes Immune Cell Response

There is an increasing role of high-intensity exercise training in cancer care. Evidence suggests that exercise can reduce side effects of treatment. And it has the added benefits of improving physical functioning and quality of life. Exercise leads to an increase of adrenalin, which also triggers a patient’s natural immune response. This can alter the tumor microenvironment and lead to reduced tumor growth. New data suggest that exercise could improve immune responses against cancer cells. It works by increasing immune cell infiltration to the tumor. And it may have an impact on disease progression. A new clinical trial has been initiated. It will investigate if high-intensity exercise can benefit patients with lung cancer. Can adrenalin mobilize and increase the infiltration … Continue reading Maximizes Your Immune Cell Response with High-Intensity Exercise »

New Drug Targeting Fibrosis may Help Mesothelioma Patients

Targeting Fibrosis in Mesothelioma has Therapeutic Benefits

Targeting fibrosis has therapeutic benefits in mesothelioma. Most drugs have limited effects in difficult-to-treat cancers such as mesothelioma. Often this is because not enough of the drug can get into the tumor to generate an anti-tumor effect. Fibrosis is a common element of mesothelioma. It causes the area around the cancer to stiffen. Fibrosis acts as a barrier, stopping drugs from getting into the cancer tumor. This limits the immune system’s ability to detect and access the tumor to kill it. A new study is looking at how a family of proteins called lysyl oxidases can help solve this problem. These proteins are associated with fibrosis in many cancers, including mesothelioma. Oncologists targeting fibrosis and this protein family may improve … Continue reading New Drug Targeting Fibrosis may Help Mesothelioma Patients »

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab »

Clinical Trial Participation: Perspectives from Mesothelioma Patients and Caregivers

Perspectives of Clinical Trial Participation from Mesothelioma Patients and Caregivers

Clinical trial participation is a common topic for mesothelioma patients and their caregivers. Treatment options for mesothelioma are increasing. This is a direct result of the number of clinical trials available to patients. Yet, little is known about patients’ and relatives’ feelings about trial participation. A new study provides insight into people’s experiences of clinical trial participation. They also report what factors influence decision-making. Scientists interviewed twelve people, comprising five mesothelioma patients and seven relatives. They identified four themes related to the experience of mesothelioma. First, is the physicality of the disease. Second, the patient’s quality of life. Third, uncertainty and risk are associated with mesothelioma. And fourth, planning for an unpredictable future. A further theme included attitudes on clinical … Continue reading Clinical Trial Participation: Perspectives from Mesothelioma Patients and Caregivers »

First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy

Chemotherapy versus Immunotherapy versus Maintenance Therapy

A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural mesothelioma is an aggressive cancer that affects older adults. Mesothelioma patients often have other comorbidities making real-world treatment decisions challenging. The first was by choice of first-line chemotherapy. The second was the physician’s choice of second-line chemotherapy versus immunotherapy. And the third was by the physician’s choice of use of maintenance therapy. Physician’s Choice of First-Line Chemotherapy Drugs This is the largest real-world study of U.S. patients diagnosed with mesothelioma. Scientists analyzed physicians’ choice of first-line chemotherapy, second-line therapy, and maintenance therapy. In the first-line chemotherapy analysis, there was no significant difference in patient survival. As of this writing, the only … Continue reading First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy »

Get your free copy of
“Surviving Mesothelioma” Today!